- About
- Projects
- Column 1
- Animal Health & Veterinary Medicine
- Expanded Access
- FDA Patient Listening Sessions
- Food & Nutrition
- Column 2
- Column 1
- News and Events
- Expanded Access eRequest
Over-the-Counter Narcan Could Save More Lives. But Price and Stigma Are Obstacles. - New York Times
If Narcan, the nasal spray that saves lives by reversing opioid overdoses, receives approval to be sold over the counter, public health officials hope the palm-size plunger could one day become as commonplace as a kitchen fire extinguisher.
2023 Innovations in Regulatory Science Awards
Join the Reagan-Udall Foundation for the FDA as we bring the regulatory science community together to recognize the leadership, scientific breakthroughs, and unwavering advocacy that helps safeguard America’s public health.
The Awards will be presented in three categories:
Biden officials flood the Hill - POLITICO
FDA ON THE HILL: Califf on Wednesday will testify before the House Appropriations Committee on Biden’s fiscal 2024 budget.
2023 Annual Public Meeting
Each year, the Reagan-Udall Foundation for the FDA conducts an Annual Public Meeting of its Board of Directors to share information about our activities in support of the U.S. Food and Drug Administration. By bringing together a variety of perspectives, the annual public meeting facilitates engagement between FDA and external stakeholders including patients and consumers, regulated industry, health care providers, academics, and others dedicated to improving America's public health.
Generating evidence for racial and ethnic minorities during development of oncologic therapeutics - Regulatory Focus
Discussions regarding diversity, equity, and inclusion in healthcare and clinical research have been ongoing for decades. However, the COVID-19 global pandemic brought about a new focus on this issue.
Inside FDA’s Response to Reagan-Udall Foundation Report: Spotlight on the Science and Application Review Task Force - LexBlog
There is a common refrain that appears throughout the Reagan-Udall Foundation report on the Center for Tobacco Products (CTP) at the Food and Drug Administration (FDA) — lack of transparency.
Even over the counter, Narcan may be too costly to reach many drug users - Washington Post
Before month’s end, federal regulators are poised to allow over-the-counter sale of a nasal spray that reverses the potentially lethal effects of an opioid overdose.
But groups that work to reduce the toll of drugs on the streets have one question: Will anybody be able to afford it?